chlorpheniramine has been researched along with dexbrompheniramine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Campi, B; Compton, SJ; Morice, AH; Sadofsky, LR; Trevisani, M | 1 |
1 review(s) available for chlorpheniramine and dexbrompheniramine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for chlorpheniramine and dexbrompheniramine
| Article | Year |
|---|---|
Transient receptor potential vanilloid-1-mediated calcium responses are inhibited by the alkylamine antihistamines dexbrompheniramine and chlorpheniramine.
Topics: Animals; Brompheniramine; Calcium; Calcium Channels; Capsaicin; Cell Line; Chlorpheniramine; Histamine Antagonists; Humans; Nerve Tissue Proteins; Rats; Rats, Sprague-Dawley; Receptor, PAR-2; Transient Receptor Potential Channels; TRPA1 Cation Channel; TRPV Cation Channels | 2008 |